甲磺酸齐拉西酮注射液对精神分裂症急性激越症状患者PANSS- EC、BARS评分及不良反应的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Ziprasidone Mesyate Injection on excited components of the positive and negative syndrome scale (PANSS-EC),behavioral activity rating scale (BARS) scores and adverse reactions in schizophrenia patients with acute agitation symptoms.Methods The clinical data of 67 schizophrenia patients with acute agitation symptoms who were admitted to our hospital from January 2019 to January 2020 were retrospectively analyzed.All the patients were divided into the control group (34 cases) and the observation group (33 cases) according to different treatment methods.The control group was given Haloperidol Injection,and the observation group was given Ziprasidone Meylate Injection.The clinical efficacy,PANSS-EC,BARS scores before and after treatment and the total incidence of adverse reactions were compared between the two groups.Results The effective rate of the observation group was 90.91%,compared with 88.24% of the control group,the difference was not statistically significant (P＞0.05).The PANSS-EC and BARS scores in two groups after treatment were lower than those before treatment,the differences were statistically significant (P＜0.05).There were no statistical differences in the PANSS-EC and BARS scores between the two groups after treatment (P＞0.05).The total incidence rate of adverse reactions in the observation group (9.09%)was lower than that in the control group,the difference was statistically significant (29.41%) (P＜0.05).Conclusion Ziprasidone Mesilate Injection in the treatment of schizophrenia patients with acute agitation symptoms has better curative effects,whose efficacy is similar to Haloperidol,but it has lower incidence of adverse reactions and better safety.

Key words： Ziprasidone Mesyate Haloperidol Schizophrenia

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YUAN Qiang

Cite this article:

YUAN Qiang. Effect of Ziprasidone Mesylate Injection on PANSS-EC,BARS scores and adverse reactions in patients with acute agitation symptoms of schizophrenia[J]. 中国当代医药, 2020, 27(31): 73-75.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I31/73

[14]	周晓坤.齐拉西酮对精神分裂症患者认知功能和生活质量的影响[J].临床合理用药杂志，2019，12（10）：68-69.
[15]	谭剑.用齐拉西酮与奥氮平治疗早期精神分裂症的效果及安全性探讨[J].当代医药论丛，2018，16（11）：117-118.
[1]	光涛，李志宏，王国威，等.注射用甲磺酸齐拉西酮治疗精神分裂症急性激越症状疗效观察[J].中国新药与临床杂志，2014，33（1）：57-60.
[2]	胡光涛，宋航，王国威，等.甲磺酸齐拉西酮与氟哌啶醇注射液治疗精神分裂症急性激越症状的对照研究[J].重庆医学，2014，43（35）：4766-4768.
[3]	中国精神科学会.中国精神障碍分类与诊断[M].济南：山东科学技术出版社，2001：75-78.
[4]	门涛.齐拉西酮注射液与氟哌啶醇注射液治疗老年精神分裂症急性激越症状的效果及安全性对比[J].中国当代医药，2019，26（1）：166-168.
[5]	方春霞，费静霞，蔡燕.以行为活动评定量表（BARS）为标准对精神病患者实施行为管理的效果评价[J].国际护理学杂志，2015，34（13）：1830-1832.
[6]	朱桂东，宋清海，徐伟杰，等.齐拉西酮联合奥氮平对老年难治性精神分裂症患者症状及血清瘦素和脑源性神经营养因子水平的影响[J].中国慢性病预防与控制，2019，27（3）：219-222.
[7]	杨玲.齐拉西酮治疗首发精神分裂症患者的临床疗效观察[J].医学临床研究，2018，35（8）：1621-1622.
[8]	孙梦夕，马骏，王潇，等.抗精神病药物治疗急性期精神分裂症的早期反应情况及相关因素的分析[J].中华医学杂志，2017，97（31）：2425-2430.
[9]	常凤坤，王会娟.齐拉西酮针剂序贯口服胶囊治疗精神分裂症激越症的效果及安全性评价[J].临床医学工程，2018，26（6）：777-778.
[10]	刘璐，程德君，原富强，等.西酞普兰联合齐拉西酮治疗精神分裂症的临床有效性及安全性观察[J].海峡药学，2018，30（5）：100-102.
[11]	陈海波，吴文艳，陈海峰.齐拉西酮联合喹硫平对女性首发精神分裂症患者临床症状及血清催乳素水平的影响[J].当代医学，2019，25（25）：94-96.
[12]	晏桂萍，朱志雾.齐拉西酮与利培酮治疗首发精神分裂症的疗效和安全性[J].中国社区医师，2018，34（17）：87-88.
[13]	王剑.阿立哌唑联合齐拉西酮治疗精神分裂症患者的临床效果[J].甘肃医药，2019，38（2）：136-137.